Skip to content

Efficacy of single dose azithromycin in the treatment of non-gonococcal urethritis in homosexual vs heterosexual men.

Efficacy of single dose 1 gram azithromycin as part of National AIDS Control Organizationâ??s urethral discharge syndrome kit in the treatment of non-gonococcal urethritis in homosexual vs heterosexual males: a prospective comparative study.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/12/029666
Enrollment
50
Registered
2020-12-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A64- Unspecified sexually transmitted disease

Interventions

Intervention1: Single dose 1 gram azithromycin and 400 mg cefixime will be given to group 1 (homosexual men): Azithromycin dose 1 gram, tablet, oral route, single dose only, duration 1 day. cefixime

Sponsors

All India Institute of Medical Sciences New Delhi
Lead Sponsor
All India Institute of Medical Sciences New Delhi
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age more than 18 years 2. Giving consent for examination and collection of urethral swabs and first void urine for microscopy, culture and or molecular methods.

Exclusion criteria

Exclusion criteria: 1. Gonococcal urethritis diagnosed as either presence of intracellular gram negative diplococci on Gram stain and or culture positivity for N. gonorrhea. 2. Presence of other sexually transmitted infections requiring another kit regimen apart from urethral discharge (kit 1) i.e. genital ulcer disease herpetic, genital ulcer disease non- herpetic, inguinal bubo. 3. Received oral antibiotics in past 15 days. 4. Patient with contraindication to receiving either cefixime or azithromycin.

Design outcomes

Primary

MeasureTime frame
Proportion of cases with clinical cure based on history, examination and bed side tests at 3 weeks follow up in the two groups. Timepoint: 3 weeks

Secondary

MeasureTime frame
Prevalence, clinical and microbiological cure rates at extra-urethral sites such as ano-rectum and oro-pharnyx, depending on the history of sexual exposure at these sites in the two groups will also be compared at 3 weeks follow up. Timepoint: 3 weeks ;Proportion of cases with clinical cure based on history, examination and bed side tests at 1 week follow up in the two groups. Timepoint: 1 week;proportion of cases with microbiological cure in the two groups. It will be calculated overall and as well as individually for each agent (Chlamydia trachomatis, Mycoplasma genitalium and Ureaplasma urealyticum) at 3 weeks follow up. Timepoint: 3 weeks;Time taken for resolution of symptoms, which will be determined from the history given by the patient based on the daily log. The first day of the symptom resolution for 5 consecutive days. It will be compared between the two groups thereafter. Timepoint: 3 weeks

Countries

India

Contacts

Public ContactDr Deepika Yadav

All India Instiute of Medical Sciences, New Delhi

deepikayadav18.90@gmail.com01126593217

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026